Tempol is under clinical development by Matrix Biomed and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Tempol’s likelihood of approval (LoA) and phase transition for Glioblastoma Multiforme (GBM) took place on 11 Jul 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tempol Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Tempol overview

Tempol is under development for the radiation-induced skin toxicity, prevention of radiation-induced oral mucositis, chemotherapy-induced toxicities, treatment of neuropathy, ataxia-telangiectasia (Louis-Bar syndrome), recurrent glioblastoma multiforme, prostate cancer, doxorubicin induced toxicities, macular degeneration, cisplatin toxicities and paclitaxel induced toxicities. The drug candidate is administered orally and topically as a capsule and as a gel. MTS-01 (Tempol) is a piperidine nitroxide. Tempol is a membrane-permeable radical scavenger. It acts by targeting HIF-1 and HIF-2. It was under development for the treatment of alopecia and depression. 

It was under development for the treatment of ARDS, cytokine storm due to COVID-19 disease.

Matrix Biomed overview

Matrix Biomed is a biopharmaceutical company focused on the development of novel gene-based therapeutics for cancer treatments. The company developed TEMPOL, a compound that reaches every cell in the body and repairs damaged cellular environments thereby increasing mitochondria output and improving overall cellular function. Its pipeline products include MTS-01, a topical gel for prevention of radiation dermatitis; MTS-02 for rectal administration; MTS-10 is a water-based mouthwash formulation of TEMPOL for the prevention of oral mucositis; MBM-01 is a liquid formulation of TEMPOL being developed for the prevention of oral mucositis and other cisplatin and radiation induced toxicities; MBM-02, a gelatin capsule developed for the prevention various chemotherapeutic induced toxicities. Matrix Biomed is headquartered in Irvine, California, the US.

Quick View Tempol LOA Data

Report Segments
  • Innovator
Drug Name
  • Tempol
Administration Pathway
  • Ophthalmic
  • Oral
  • Topical
Therapeutic Areas
  • Central Nervous System
  • Dermatology
  • Gastrointestinal
  • Infectious Disease
  • Oncology
  • Ophthalmology
  • Toxicology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.